Trial Profile

A Phase I Study of Ceritinib (LDK378), a Novel ALK Inhibitor, in Combination With Gemcitabine-Based Chemotherapy in Patients With Advanced Solid Tumors

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 27 Jul 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ceritinib (Primary) ; Cisplatin (Primary) ; Gemcitabine (Primary) ; Paclitaxel (Primary)
Indications Adenocarcinoma; Advanced breast cancer; Carcinoma; Cholangiocarcinoma; Head and neck cancer; Leiomyosarcoma; Liver cancer; Pancreatic cancer; Solid tumours
Focus Adverse reactions

Most Recent Events

15 Dec 2021 Results published in the International Journal of Cancer
28 Apr 2020 Interim results presented at the 111th Annual Meeting of the American Association for Cancer Research - I
04 Feb 2020 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com